Biokhimik

Biokhimik is a leading Russian pharmaceutical manufacturer and the primary production asset of the Promomed Group. Founded in 1952 and based in Saransk, the company operates a sophisticated full-cycle manufacturing facility that spans from active pharmaceutical ingredient (API) synthesis to finished dosage forms across ten different formats. Biokhimik specializes in a wide range of therapeutic areas, including endocrinology, infectious diseases, oncology, and neurology, with a portfolio of over 300 medicines. The company is notably recognized for its leadership in the obesity treatment segment and its rapid response to the COVID-19 pandemic through the production of advanced antivirals. Supported by a robust R&D hub, Biokhimik continues to expand its capabilities into biotechnological products and innovative small molecules to ensure national drug security.